Immunotherapy for Renal Cell Carcinoma

This publication has 102 references indexed in Scilit:

• Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
  Cancer Research, 2010
• Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
  Blood, 2009
• Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
  Clinical Cancer Research, 2009
• PD-1 and Its Ligands in Tolerance and Immunity
  Annual Review of Immunology, 2008
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
  The Lancet, 2007
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8⁺T lymphocytes are prognostic factors of human ovarian cancer
  Proceedings of the National Academy of Sciences, 2007
• Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
  New England Journal of Medicine, 2007
• Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice
  British Journal of Ophthalmology, 2006
• Tissue expression of PD-L1 mediates peripheral T cell tolerance
  Journal of Experimental Medicine, 2006
• Mechanisms and functional significance of tumour-induced dendritic-cell defects
  Nature Reviews Immunology, 2004